[1]Gaudry S, Palevsky PM, Dreyfuss D. Extracorporeal Kidney-Replacement Therapy for Acute Kidney Injury[J]. N Engl J Med, 2022, 386(10): 964‐975
[2]杨艳丽, 徐元恺, 户培华, 等. 基于血管重构的纤细动脉自体动静脉内瘘成熟影响因素分析[J]. 中国血液净化, 2024, 23 (04): 299-302+317.
[3]Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update[J]. Am J Kidney Dis, 2020, 75(4 Suppl 2): S1-S164.
[4]de Rooij ENM, Meuleman Y, de Fijter JW, et al. Symptom Burden before and after Dialysis Initiation in Older Patients[J]. Clin J Am Soc Nephrol, 2022, 17(12): 1719–1729.
[5]Lawson JH, Niklason LE, Roy-Chaudhury P. Challenges and novel therapies for vascular access in haemodialysis[J]. Nat Rev Nephrol, 2020, 16(10): 586-602.
[6]Canaud B, Davenport A, Golper TA. On-line hemodiafiltration therapy for end-stage kidney disease patients: Promises for the future? What's next?[J]. Semin Dial, 2022, 35(5): 459-460.
[7]Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, et al. Epidemiology of Antiphospholipid Syndrome in the General Population[J]. Curr Rheumatol Rep, 2022, 23(12): 85.
[8]Ames PRJ, Merashli M, Bucci T, et al. Antiphospholipid antibodies in end-stage renal disease: A systematic review and meta-analysis[J]. Hemodial Int, 2020;24(3): 383-396.
[9]杜丰禾, 刘暴. 血管周围脂肪组织炎性反应促进动脉粥样硬化作用机制的研究进展[J]. 基础医学与临床, 2023. 43(4): 685-689
[10]ZHANG F, GUO XQ, XIA YP, et al. An update on the phenotypic switching of vascular smooth muscle cells in the pathogenesis of atherosclerosis[J]. Cell Mol Life Sci, 2021, 79(1): 6.
[11]白伊娜, 孟菁菁, 赵久良, 等. 抗磷脂综合征中非标准抗磷脂抗体的诊断价值和风险预测[J]. 中华临床免疫和变态反应杂志, 2023, 17 (05): 395-406.
[12]崔佳, 张明明, 王娜, 等. 糖脂代谢指标联合抗磷脂抗体对动脉粥样硬化患者预后的预测价值[J]. 实用医学杂志, 2024, 40 (03): 326-329.
[13]Erton ZB, Erkan D. Treatment advances in antiphospholipid syn-drome: 2022 update[J]. Curr Opin Pharmacol, 2022, 65: 102212.
[14]Knight JS, Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome[J]. Semin Immunopathol, 2022, 44(3): 347-362.
[15]Cheng CY, Cheng GY, Denas G, et al. Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review[J]. Blood Rev, 2021, 48: 100788.
[16]Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management[J]. BMJ, 2023, 380: e069717.
[17]Huang S, Ninivaggi M, Chayoua W, et al. VWF, Platelets and the Antiphospholipid Syndrome[J]. Int J Mol Sei, 2021, 22(8): 4200.
[18]Barbhaiya M, Zuily S, Naden R, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria[J]. Ann Rheum Dis, 2023, 82(10): 1258-1270.
[19]Liu XJ, Zhu L, Liu HJ, et al. Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added[J]. Front Immunol, 2022, 13: 972012. .
[20]Gameiro J, Ibeas J. Factors affecting arteriovenous fistula dysfunction: A narrative review[J]. J Vasc Access, 2020, 21(2): 134-147.
[21]Vazquez-Padron RI, Duque JC, Tabbara M, et al. Intimal Hyperplasia and Arteriovenous Fistula Failure: Looking Beyond Size Differences[J]. Kidney360, 2021, 2(8): 1360-1372.
[22]Ma SJ, Duan SZ, Liu Y, et al. Intimal Hyperplasia of Arteriovenous Fistula[J]. Ann Vasc Surg, 2022, 85: 444-453.
[23]Anapalli SR, N HD, Sarma P, et al. Thrombophilic risk factors and ABO blood group profile for arteriovenous access failure in end stage kidney disease patients: a single-center experience[J]. Ren Fail, 2022, 44(1): 34-42.
[24]Sosińska-Zawierucha P, Br?borowicz A. Uremic serum induces prothrombotic changes in venous endothelial cells and inflammatory changes in aortic endothelial cells[J]. Ren Fail, 2021, 43(1): 401-405. .
[25]Barbhaiya M, Taghavi M, Zuily S, et al. Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report[J]. J Rheumatol, 2024, 51(2): 150-159. .
[26]Gkrouzman E, Sevim E, Finik J, et al. Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository[J]. J Rheumatol, 2021, 48(4): 541-547.
[27]Almajdi A, Almutairi S, Alharbi M. Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis[J]. Thromb Res, 2023, 229: 77-85.
[28]Porta SV, de Andrade DCO, Erkan D, et al. Controversies in the Management of Antiphospholipid Syndrome[J]. J Clin Rheumatol, 2023, 29(5): e107-e112.
[29]Chia CKA, Tay HT. Endovascular salvage of a chronically thrombosed hemodialysis arteriovenous fistula[J]. J Vasc Surg Cases Innov Tech, 2024, 10(3): 101472.
[30]Huber TS, Berceli SA, Scali ST, et al. Arteriovenous Fistula Maturation, Functional Patency, and Intervention Rates[J]. JAMA Surg, 2021, 156(12): 1111-1118.
[31]Suraj HS, Kumar SA, Rachegowda N, et al. Role of Doppler Evaluation in Assessing the Maturation of the Arteriovenous Fistula for Hemodialysis: An Observational Study[J]. Cureus, 2024, 16(3): e55527.
[32]Zonnebeld N, Huberts W, Loon MMV, et al. Natural Vascular Remodelling After Arteriovenous Fistula Creation in Dialysis Patients With and Without Previous Ipsilateral Vascular Access[J]. Eur J Vasc Endovasc Surg, 2020, 59(2): 277-287
[33]Taghavi M, Demulder A, Mesquita M, et al. Underestimated effect of antiphospholipid antibodies on arteriovenous fistula maturation in hemodialysis patients[J]. Research Square (Research Square), 2022.
[34]Evangelatos G, Kravvariti E, Konstantonis G, et al. Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3 year prospective study[J]. Rheumatology (Oxford), 2022, 61(8): 3408-3413.
[35]Sorice M, Profumo E, Capozzi A, et al. Oxidative Stress as a Regulatory Checkpoint in the Production of Antiphospholipid Autoantibodies: The Protective Role of NRF2 Pathway[J]. Biomolecules, 2023, 13(8): 1221.
[36]Tullavardhana T, Chartkitchareon A. Meta-analysis of total versus partial graft excision: Which is the better choice to manage arteriovenous dialysis graft infection?[J]. Ann Saudi Med, 2022, 42(5): 343-350.
[37]Shahri JJ, Saberianpour S, Kazemzadeh G. Arteriovenous Fistula Aneurysm: Bench to Bedside[J]. Indian J Surg, 2023, 85?(Suppl 1), 219–227.
[38]Askary ZM, Abdelhady M, YousefMA, et al. Influence of native upper limb hemodialysis arteriovenous fistula on left ventricle[J]. Ital J Vasc Endovasc Surg, 2022, 29(2): 70-73.
[39]Stoumpos S, Rankin A, Hall Barrientos P, et al. Interrogating the haemodynamic effects of haemodialysis arteriovenous fistula on cardiac structure and function[J]. Sci Rep, 2021, 11(1): 18102.
[40]Stoecker JB, Li X, Clark TWI, et al. Dialysis Access-Associated Steal Syndrome and Management[J]. Cardiovasc Intervent Radiol, 2023, 46(9): 1168-1181.
